Optimization of monogenic diabetes screening programme - Initial report on recruitment efficacy of the TEAM project;Optymalizacja programu poszukiwania cukrzyc monogenowych - Wstȩpne wyniki działań rekrutacyjnych projektu TEAM

Pediatric Endocrinology, Diabetes and Metabolism

Volumn 16, Issue 2, 2010, Pages 73-76

  Borowiec, Maciej ^a   Fendler, Wojciech ^a   Antosik, Karolina ^a   Ciepiela, Anna ^a   Baranowska, Anna ^a   Hogendorf, Anna ^a   Mianowska, Beata ^a   Szadkowska, Agnieszka ^a   Młynarski, Wojciech ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

MODY; Neonatal diabetes; Pharmacogenetics

Indexed keywords

AUTOANTIBODY; C PEPTIDE; PANCREAS ISLET CELL ANTIBODY;

ARTICLE; CLINICAL ASSESSMENT; DIABETES MELLITUS; DISEASE COURSE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GENETIC SCREENING; GENETIC SELECTION; HUMAN; IMMUNOLOGICAL PARAMETERS; INHERITANCE; MAJOR CLINICAL STUDY; MATURITY ONSET DIABETES MELLITUS; MONOGENIC DISORDER; MORBIDITY; PATIENT SELECTION; PHYSICIAN; PROCESS OPTIMIZATION; SCREENING; CLASSIFICATION; DIABETES MELLITUS, TYPE 1; GENETICS; IMMUNOLOGY; INCIDENCE; MASS SCREENING; ORGANIZATION AND MANAGEMENT; PANCREAS ISLET BETA CELL; PROCEDURES;

AUTOANTIBODIES; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; GENETIC TESTING; HUMANS; INCIDENCE; INSULIN-SECRETING CELLS; MASS SCREENING; PATIENT SELECTION;

EID: 84904850213     PISSN: 1234625X     EISSN: 20838441     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Froguel P., Zouali H., Vionnet N. i wsp.: Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N. Engl. J. Med., 1993, 328, 697-702.
2. Velho G., Blanche H., Vaxillaire M. i wsp.: Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 1997, 40, 217-224.
3. Matschinsky F.M.: Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes, 2002, 51 (supl. 3), 394-404.
4. Velho G., Froguel P.: Maturity-onset diabetes of the young (MODY), MODY genes and noninsulin- dependent diabetes mellitus. Diabetes Metab., 1997, 23 (supl. 2), 34-37.
5. Gloyn A.L.: Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum. Mutat., 2003, 22, 353-362.
6. Yamagata K., Oda N., Kaisaki P.J. i wsp.: Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature, 1996, 384, 455-458.
7. Stoffers D.A., Ferrer J., Clarke W.L., Habener J.F.: Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat. Genet., 1997, 17, 138-139.
8. Horikawa Y., Iwasaki N., Hara M. i wsp.: Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat. Genet., 1997, 17, 384-385.
9. Malecki M.T., Jhala U.S., Antonellis A. i wsp.: Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat. Genet., 1999, 23, 323-328.
10. Stoy J., Edghill E.L., Flanagan S.E. i wsp.: Insulin gene mutations as a cause of permanent neonatal diabetes. Proc. Natl. Acad. Sci. USA, 2007, 104, 15040-15044.
11. Gloyn A.L., Pearson E.R., Antcliff J.F. i wsp.: Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med., 2004, 350, 1838-1849.
12. Babenko A.P., Polak M., Cave H. i wsp.: Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N. Engl. J. Med., 2006, 355, 456-466.
13. Sagen J.V., Raeder H., Hathout E. i wsp.: Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes, 2004, 53, 2713-2718.
14. Gach A., Wyka K., Pietrzak I. i wsp.: Neonatal diabetes in a child positive for islet cell antibodies at onset and Kir6.2 activating mutation. Diabetes Res. Clin. Pract., 2009, 86, e25-e27.